Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes

Trial Profile

Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top